The state of Florida currently has 14 active clinical trials seeking participants for COPD research studies. These trials are conducted in various cities, including Miami, Tampa, Jacksonville and Orlando.
A Study to Evaluate Solrikitug in Participants With COPD (ZION)
Recruiting
A Randomized, Double-blind, Placebo-controlled, Multiple Dose-Ranging Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Solrikitug in Participants with Chronic Obstructive Pulmonary Disease (COPD).
Gender:
ALL
Ages:
Between 40 years and 75 years
Trial Updated:
08/07/2025
Locations: Research Site 049, Clearwater, Florida +12 locations
Conditions: COPD
An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema
Recruiting
This is a prospective, open-label, multi-center, single-arm study planned to enroll 200 subjects with heterogeneous emphysema and collateral ventilation (CV) in the target lobe. Subjects will undergo instillation of AeriSeal Foam in the target lobe and subsequent assessment of CV status using Chartis Pulmonary Assessment System. Subjects with CV- status will then undergo placement of Zephyr Valve in the target lobe for bronchoscopic lung volume reduction (BLVR) and be followed for 24 months.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
08/05/2025
Locations: Orlando Health, Orlando, Florida
Conditions: Emphysema, Pulmonary, Emphysema or COPD
A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD
Recruiting
This study is testing the safety, tolerability, pharmacokinetics and pharmacodynamics of GB-0895.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/04/2025
Locations: Alcanza, DeLand, Florida +2 locations
Conditions: Asthma, COPD (Chronic Obstructive Pulmonary Disease)
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
Recruiting
This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COPD) who are former or current smokers and have a history of frequent exacerbations.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
08/01/2025
Locations: Cornerstone Research Institute, Altamonte Springs, Florida +13 locations
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).
Recruiting
Subjects who completed either OBERON or TITANIA will be offered the opportunity to consent for this Multicentre, Double-blind, Randomised, Placebo controlled, Parallel Group, Phase 3, extension study to evaluate the safety and efficacy of Tozorakimab in adult participants with symptomatic COPD.
Gender:
ALL
Ages:
Between 40 years and 130 years
Trial Updated:
07/31/2025
Locations: Research Site, Boynton Beach, Florida +7 locations
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
Recruiting
The purpose of this randomized study is to demonstrate direct clinical benefit, i.e., observed benefits in how humans with COPD feel in terms of symptoms (e.g., cough frequency, shortness of breath, and other respiratory symptoms) and function (e.g., lung function, and six-minute walking test \[6MWT\]) after switching to THS compared to continuing to smoking cigarettes.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
07/31/2025
Locations: Florida International Medical Research, Coral Gables, Florida +14 locations
Conditions: COPD, Smoking, Tobacco Use
Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3
Recruiting
The objective of this study is to assess the safety and efficacy of Apreo BREATHE system when used to support native airways and release trapped air in the treatment of adult COPD patients with emphysema suffering from dyspnea due to hyperinflation despite optimal medical treatment. The Apreo BREATHE Airway Scaffold is a permanent implant designed to tent open native airways. The study will include up to 250 participants at up to 25 study centers located in the United States and Europe. Study su... Read More
Gender:
ALL
Ages:
Between 40 years and 84 years
Trial Updated:
07/29/2025
Locations: Mayo Clinic, Jacksonville, Florida +1 locations
Conditions: COPD, Emphysema
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
Recruiting
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
07/23/2025
Locations: Research Site, Bay Pines, Florida +12 locations
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD
Recruiting
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
07/22/2025
Locations: Research Site, Cutler Bay, Florida +9 locations
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
Recruiting
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
07/18/2025
Locations: Research Site, Boynton Beach, Florida +38 locations
Conditions: COPD (Chronic Obstructive Pulmonary Disease)
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Recruiting
This Phase IIb dose-ranging study will evaluate the efficacy and safety of 3 different doses of AZD6793 compared with placebo tablets in participants with moderate to very severe chronic obstructive pulmonary disease.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
07/16/2025
Locations: Research Site, Cape Coral, Florida +19 locations
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)
Recruiting
This is a Phase 2, multicenter study in adult participants with an acute COPD exacerbation and type 2 inflammation
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
05/07/2025
Locations: Synergy Healthcare, Bradenton, Florida
Conditions: COPD Acute Exacerbation